GPT and Thrombophlebitis: In total, seven patients withdrew from the study due to AEs during the treatment phase, all in the GSK239512 group [insomnia (n = 2), thrombophlebitis (n = 1), cough (n = 1)], elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST; n = 1), thymoma (n = 1) and, axillary candidiasis, dry mouth, toxic skin eruption and xerosis (n = 1)].